On October 13, Johnson & Johnson fell 3.14% in Regular Trading, trading at $253.285 per share, with turnover of $187 million.

The move followed the company’s third-quarter report and management’s updated remarks on its orthopaedics portfolio. Johnson & Johnson reported Q3 sales of $25.4 billion, roughly in line with expectations, while adjusted EPS of $2.59 came in above consensus. The company also raised full-year sales guidance to $101.0 billion-$101.4 billion and adjusted EPS guidance to $11.05-$11.15.

Despite the beat-and-raise quarter, the stock’s decline widened after management said it prefers a separation of the hips and knees business rather than a sale, with plans to complete the transaction around mid-next year. The development suggests MedTech portfolio reshaping remains in focus, and investors may be reassessing the impact on Johnson & Johnson’s growth mix and valuation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)